Kay Sigi, Herishanu Yair, Pick Marjorie, Rogowski Ori, Baron Shoshana, Naparstek Elizabeth, Polliack Aaron, Deutsch Varda R
The Hematology Institute, Tel Aviv Sourasky Medical Center,Tel Aviv, Israel.
Cytometry B Clin Cytom. 2006 Jul 15;70(4):218-26. doi: 10.1002/cyto.b.20078.
ZAP-70 has emerged as a potential pivotal prognostic marker for patients with chronic lymphocytic leukemia (CLL), which could replace immunoglobulin heavy chain mutation status. Although several flow cytometry assays have been described for assessing ZAP-70 in CLL, certain technical and scientific issues remain unsolved, which have prevented results of this crucial test from being reported, even in the best routine flow cytometry laboratories. In this report, we aimed to solve some of these issues by providing a computerized quantitative flow cytometric assay for ZAP-70 within the entire CLL population, which would be easy to perform and enable standardization between laboratories.
Intracellular ZAP-70 levels in CLL and normal B cells were assessed by molecules of equivalent soluble fluorochrome (MESF), employing Quantum FITC MESF calibration beads to establish a standard curve relating channel value to fluorescence intensity in MESF units and the QuickCal v. 2.2 program (www.bangslabs.com) and clinical relevance of the data was determined.
The average ZAP-70 expression value in the CD19(+)/CD5(+) cells from 35 CLL patients was 103,701 MESF when compared with 12,621 MESF in B cells from 20 normal blood samples. "Low" and "high" ZAP-70 CLL subgroups were defined. Patients with "high ZAP-70 MESF" CLL had a shorter time to disease progression (P = 0.0005) and a more advanced clinical stage (P = 0.0018) when compared with patients in the "low ZAP-70 MESF" CLL subgroup.
This quantitative analysis method can be employed to obtain a more specific and highly accurate assessment of ZAP-70 levels in CLL cells. The method can easily be standardized, in any routine flow laboratory, thereby improving reproducibility and reliability of ZAP-70 analysis.
ZAP-70已成为慢性淋巴细胞白血病(CLL)患者潜在的关键预后标志物,可取代免疫球蛋白重链突变状态。尽管已有多种流式细胞术检测方法用于评估CLL中的ZAP-70,但仍存在一些技术和科学问题尚未解决,这使得即使在最佳的常规流式细胞术实验室中,这项关键检测的结果也无法报告。在本报告中,我们旨在通过为整个CLL群体提供一种计算机化的ZAP-70定量流式细胞术检测方法来解决其中一些问题,该方法易于操作且能实现实验室间的标准化。
采用等效可溶性荧光染料分子(MESF)评估CLL细胞和正常B细胞内的ZAP-70水平,使用量子FITC MESF校准微球建立通道值与MESF单位荧光强度之间的标准曲线,并使用QuickCal v. 2.2程序(www.bangslabs.com),同时确定数据的临床相关性。
35例CLL患者的CD19(+)/CD5(+)细胞中ZAP-70的平均表达值为103,701 MESF,而20份正常血样的B细胞中该值为12,621 MESF。定义了“低”和“高”ZAP-70 CLL亚组。与“低ZAP-70 MESF”CLL亚组患者相比,“高ZAP-70 MESF”CLL患者疾病进展时间更短(P = 0.0005),临床分期更晚(P = 0.0018)。
这种定量分析方法可用于更特异、准确地评估CLL细胞中ZAP-70的水平。该方法在任何常规流式实验室中都能轻松实现标准化,从而提高ZAP-70分析的可重复性和可靠性。